|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Importantly, although Mitf E318K was not sufficient to cooperate with BRaf V600E alone in promoting metastatic melanoma, it accelerated tumor formation on a BRaf V600E , Pten-deficient background (median survival, Mitf E318K/+ = 42 days, 95% CI = 31 to 46 vs Mitf WT = 51 days, 95% CI = 50 to 55, P < .001).
|
28376192 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Diffuse melanosis cutis in the setting of BRAF(V600E) metastatic melanoma.
|
25257244 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Control of BRAF(V600E) metastatic melanoma by BRAF inhibitor (BRAF-I) is limited by intrinsic and acquired resistance.
|
24732172 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation.
|
23581649 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Methotrexate sensitizes drug-resistant metastatic melanoma cells to <i>BRAF</i> V600E inhibitors dabrafenib and encorafenib.
|
29568360 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive.
|
26208524 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In contrast to patients with BRAF V600E-mutated metastatic melanoma, only 5% of patients with BRAF V600E-mutated mCRC responded to BRAF inhibitor monotherapy in an early-phase trial.
|
31219603 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Detection of the BRAF V600E mutation is required for use of the BRAF inhibitor, vemurafenib, in patients with metastatic melanoma.
|
23994118 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The development of RAF inhibitors targeted against BRAF V600E mutant melanoma cells has revolutionized the treatment of MM.
|
23174497 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Keratoacanthomas (KAs) and cutaneous squamous cell carcinomas (cuSCCs) develop in 15-30% of patients with BRAF(V600E) metastatic melanoma treated with BRAF inhibitors (BRAFi).
|
24345644 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intrinsic and acquired resistance of metastatic melanoma to (V600E/K)BRAF and/or MEK inhibitors, which is often caused by activation of the PI3K/AKT survival pathway, represents a major clinical challenge.
|
26790143 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
We describe a 50-year-old Hispanic woman with BRAF V600E mutant metastatic melanoma who was treated with surgery, radiation therapy, interleukin-2, and was enrolled on a BRAFi (dabrafenib) trial.
|
25839886 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Vemurafenib, a BRAF inhibitor, is FDA-approved for the treatment of metastatic melanoma in patients who harbor the BRAF V600E mutation.
|
25942671 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF/MEK inhibition is a standard of care for patients with <i>BRAF</i> V600E/K-mutated metastatic melanoma.
|
31580757 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
|
22235286 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Dabrafenib plus trametinib significantly prolonged progression-free survival (PFS) and overall survival (OS), improved objective response rates (ORRs) and preserved health-related quality of life (HR-QOL) to a greater extent than dabrafenib (in the double-blind COMBI-d study) and vemurafenib (in the open-label COMBI-v study) in two large, randomized, phase III studies in treatment-naïve patients with unresectable or metastatic melanoma with BRAF (V600E/K) mutation.
|
27246822 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The selective BRAF inhibitors vemurafenib and dabrafenib yield high response rates and improved overall survival in patients with BRAF V600E-mutant metastatic melanoma.
|
26857260 |
2016 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
|
26512791 |
2015 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation.
|
22293660 |
2012 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study investigated the sensitivity and specificity of immunohistochemical (IHC) analysis using an anti-BRAF antibody to detect the presence of the BRAF V600E mutation in patients with metastatic melanoma.
|
23026937 |
2013 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Assessment of BRAF p.V600E mutational status has become necessary for treatment of patients with metastatic melanoma.
|
23651150 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Due to the BRAF (V600E) mutation in her tumor and her poor functional status, we offered her off-label treatment with vemurafenib, a BRAF inhibitor approved for use in metastatic melanoma.
|
24888229 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here, we describe a patient with BRAF-V600E-positive metastatic melanoma who was sequentially treated with BRAF/MEK inhibitors (dabrafenib/trametinib) and checkpoint inhibitor immunotherapy (nivolumab, followed by pembrolizumab).
|
31082388 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although vemurafenib has been shown to improve the overall survival of patients with metastatic melanoma harboring the BRAF V600E mutation, its efficacy is often hampered by drug resistance acquired within a relatively short period through several distinct mechanisms.
|
30920401 |
2019 |